Hook & thesis
Cohu has pulled back sharply from a recent multi-year high and now trades at $59.29 after a violent intraday move. That decline looks disproportionate to what we understand about the company's exposure to AI-driven test demand. Test equipment tied to high-bandwidth memory (HBM) and other AI-specific parts is an outsized margin opportunity for Cohu - and management has already signaled margin improvement ahead. For traders willing to accept a measured risk, this dip sets up an asymmetric trade: limited downside to the stop and a clear upside toward the recent high near $74.60 if orders for AI-related test gear accelerate.
Thesis in one line: Buy Cohu at the dip to $59.29 with a stop at $52.00 and a target at $74.00 — the trade bank on incremental AI/HBM demand and management's margin recovery roadmap, while respecting macro and semiconductor cyclic risk.
What Cohu does and why the market should care
Cohu is a back-end semiconductor equipment and services provider focused on test and handling capital equipment, interface products and services. Practically, that means Cohu builds the machinery and test interfaces that validate chips before they ship. In the current cycle, AI workloads are driving demand for high-performance memory (HBM) and specialty logic — segments that require specialized test equipment. Customers ordering HBM-capable test solutions are high-value, often with better mix and margin than commodity test work.
The market should care because the semiconductor test layer sits directly in the supply chain where AI-specific chips are validated. When AI chip volumes expand, test demand can accelerate quickly and convert into meaningful revenue and margin improvements for suppliers like Cohu.
Facts and numbers that support the trade
- Market capitalization is roughly $2.80B and enterprise value about $2.88B, which implies the market is assigning a premium to Cohu relative to small-cap equipment peers given its AI exposure.
- Recent reported revenue beats and growth: the company posted $122.2M in revenue in Q4 with 30% year-over-year growth, and historical beats show the business can print upside in better cycle pockets.
- Free cash flow is positive at about $40.17M — that’s real cash generation even while the company invests in product development for HBM/test solutions.
- Management commentary pointed to margin improvement - they forecast gross margins recovering toward ~45% in the coming quarter(s) and flagged expected HBM product sales of $15-20M for the full year.
- Balance sheet: debt-to-equity sits at 0.38 and working capital liquidity (current ratio ~6.43, quick ratio ~5.31) suggest the company has flexibility to navigate near-term cycles and support product development and aftermarket services.
- Valuation metrics: price-to-sales is ~5.81 and price-to-cash-flow ~53.6, with price-to-free-cash-flow ~69.6 — these multiples are rich, but they reflect the market’s expectation for higher-margin, AI-related revenue mix.
How to think about valuation
At a $2.8B market cap and EV about $2.88B, Cohu is trading at roughly 6x EV/sales and a high P/FCF. Those multiples are elevated for a tool-maker with negative trailing EPS (GAAP EPS -$1.18), but skew toward the premium assigned to scarce suppliers of AI-capable test equipment. Without a direct peer table in this note, think of valuation as forward-looking: if AI-specific test revenues (HBM and similar) scale from low-double-digit millions to materially more, the multiple can be justified; if demand disappoints and margins remain depressed, valuation will re-rate downward. The market is already pricing a recovery — our trade is a tactical bet that the recovery holds through upcoming order wins and margin print(s).
Recent market action and positioning
Cohu ran into a pullback back to $59.29 after trading up into the $70s as the stock digested strong year-to-date gains. Insider activity showed a Cohu director sold 10,257 shares at $44.85 on 05/20/2026 — clearly profit-taking given the run. Short interest is notable: the most recent settlement shows ~8.10M shares short, with days-to-cover around 4.85, which can amplify volatility in either direction during order-flow or earnings events.
Catalysts to drive the trade
- Order announcements and design wins for HBM-specific test systems. Even incremental disclosed design wins in the $10-30M range would show tangible demand and improve visibility on the higher-margin mix.
- Quarterly results or management commentary that reiterate margin improvement toward ~45% and HBM revenue targets ($15-20M guidance for the full year was previously cited).
- Broader strength in AI chip demand or a positive read across from wafer-fab and memory equipment orders that lifts supplier sentiment.
- Any incremental aftermarket or service contract wins that stabilize recurring revenue and shorten the path to improved cash conversion.
Trade plan (actionable)
Entry: buy at $59.29.
Stop loss: $52.00 (hard stop).
Target: $74.00 (take-profit).
Position thesis timeframe: mid term (45 trading days). I expect this trade to play out over the next ~45 trading days because order flows and design-win news typically surface in quarterly cadence and mid-cycle customer announcements; if the thesis accelerates, the target is set at the recent multi-year high near $74.60 to capture the upside. If news flow is slower, the position can be reevaluated at the 45-day mark and converted to a longer hold only if order momentum and margin improvements are visible.
Rationale for levels: Entry at the current market price captures the dip and keeps risk tight. The stop at $52 is under the $54.12 50-day SMA and provides room for intraday noise while protecting capital if demand signals fade. The $74 target is near the 52-week high and represents a logical technical and fundamental upside if AI-related orders continue to accelerate.
Risk management and position sizing
This is a medium-risk trade: the company has real exposure to a hot end market (AI) but also carries execution and cyclicality risk typical of semiconductor equipment suppliers. Keep position size appropriate for your risk tolerance — this trade should not be a portfolio core position unless you have high conviction or a longer-term thesis.
Risks and counterarguments
- Market cyclicality: Semiconductor equipment spending is cyclical. If end-market demand for mobile, automotive or memory softens, test equipment orders can evaporate quickly and push revenue and margins lower.
- Execution risk on HBM products: HBM test systems are complex; delivery timelines, qualification delays or competitive losses could push expected $15-20M HBM revenue later into the year or shrink expected margins.
- Valuation is elevated: With price-to-sales ~5.8 and price-to-free-cash-flow near 70x, the stock is priced for material growth and margin expansion. Any missed guide or downward revision could trigger a sharp re-rating.
- Short crowd and volatility: Meaningful short interest (over 8M shares at the most recent settlement) can exacerbate downside on negative news but also make the name volatile; chop will likely increase near earnings or order announcements.
- Macro / capital spending risk: Broad weakness in semiconductor capex and OEM budgets would undercut order momentum regardless of AI tailwinds.
- Counterargument: A skeptical view is that the market has already priced in most of the AI tailwind — analyst price targets in prior periods averaged closer to $30-$40 historically, and the company still posted an unexpected adjusted loss in previous quarters. If AI demand is concentrated among a few large customers and does not broaden, the company may struggle to sustain the higher valuation multiple. In that view, the smart play is to wait for clearer evidence of recurring HBM orders and recurring margin expansion before initiating a long.
What would change my mind
I will abandon this trade thesis if management provides updated guidance that pushes expected HBM revenue materially below the $15-20M range or if quarterly gross margins are revised down and there is meaningful deterioration in free cash flow trends. Conversely, I will upgrade conviction if the company reports a multi-million-dollar disclosed HBM design win, reiterates or raises margin targets, and shows sequential improvement in gross margins and FCF conversion.
Bottom line
Cohu’s pullback to $59.29 creates a tactical buying opportunity for traders willing to accept semiconductor-cycle risk. The trade is a mid-term (45 trading days) swing that targets a re-test of the $74 area, backed by the potential for HBM and AI-driven test orders to lift margins and earnings. Keep the stop at $52 to limit downside and watch order flow and margin prints closely — those are the binary items that will decide the trade’s outcome.
| Metric | Value |
|---|---|
| Current price | $59.29 |
| Market cap | $2.80B |
| Enterprise value | $2.88B |
| Recent quarterly revenue (Q4) | $122.2M (up 30% YoY) |
| Free cash flow | $40.17M |
| GAAP EPS (trailing) | -$1.18 |
| Price-to-sales | ~5.81 |
| Debt-to-equity | 0.38 |
Trade ticket summary: Long COHU at $59.29; stop $52.00; target $74.00; horizon mid term (45 trading days).
Watch the next order/disclosure cadence closely. The trade depends on tangible HBM/test traction and sequential margin improvement — without those, the valuation will remain vulnerable.